Truist Financial Corp Invests $48,000 in Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

Truist Financial Corp bought a new position in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY – Get Rating) during the first quarter, according to its most recent filing with the SEC. The fund bought 37,462 shares of the company’s stock, valued at approximately $48,000. Truist Financial Corp owned 0.25% of Unicycive Therapeutics at the end of the most recent reporting period.

Analyst Upgrades and Downgrades

Separately, HC Wainwright started coverage on Unicycive Therapeutics in a research note on Wednesday, June 8th. They set a “buy” rating and a $9.00 target price on the stock.

Unicycive Therapeutics Stock Performance

Shares of Unicycive Therapeutics stock opened at $0.74 on Monday. Unicycive Therapeutics, Inc. has a 52-week low of $0.62 and a 52-week high of $3.38. The stock’s 50-day simple moving average is $0.88 and its 200 day simple moving average is $1.11. The stock has a market capitalization of $11.12 million and a P/E ratio of -0.81.

Unicycive Therapeutics (NASDAQ:UNCY – Get Rating) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). Equities research analysts forecast that Unicycive Therapeutics, Inc. will post -1.1 EPS for the current fiscal year.

Unicycive Therapeutics Profile

(Get Rating)

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Featured Articles

• Get a free copy of the StockNews.com research report on Unicycive Therapeutics (UNCY)
• Use These To Find Your Stock’s Support and Resistance Levels
• Is Boeing Stock is Ready for Lift-Off ?
• Elon Musk is Out, But Should You Be In Twitter Stock?
• 3 Earnings Announcements That Could Surprise
• Twitter’s Up For Third Week In A Row: What’s Next For The Stock?

Want More Great Investing Ideas?